Next 10 |
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentati...
2024-05-05 05:14:07 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Conference Call May 2, 2024 05:00 PM ET Company Participants Lisa DeFrancesco - Head of Investor Relations and Strategy Lonnel Coats - Chief Executive Officer and Director Jeffrey Wade -...
2024-05-02 16:32:39 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Lexicon Pharmaceuticals Q1 2024 Earnings Preview Lexicon stock slides 8% after rallying 30% in prior session Seeking Alpha’s ...
Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of sotagliflozin...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-29 09:09:09 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Lexicon stock slides 8% after rallying 30% in prior session Lexicon stock rallies 18% amid FDA update, $250M private placement Seeki...
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th...
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p....
2024-04-22 10:01:12 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Tech advances are catalyzing the Health Care sector with improved ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the Bank...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentati...